Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in JapanHiroyoshi Yokoi, Michael D. Dake, Takao Ohki et al.|JACC: Cardiovascular Interventions|2016Cited by 70
Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year ResultsKimihiko Kichikawa, Michael D. Dake, Hiroyoshi Yokoi et al.|CardioVascular and Interventional Radiology|2018Cited by 30
Long-Term Effectiveness of the Zilver PTX Drug-Eluting Stent for Femoropopliteal Peripheral Artery Disease in Patients with No Patent Tibial Runoff Vessels—Results from the Zilver PTX Japan Post-Market Surveillance StudyStefano Cipollari, Michael D. Dake, Hiroyoshi Yokoi et al.|Journal of Vascular and Interventional Radiology|2017Cited by 18
Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in JapanYukihisa Ogawa, Michael D. Dake, Hiroyoshi Yokoi et al.|CardioVascular and Interventional Radiology|2017Cited by 15
Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance StudyMasayuki Sugimoto, Michael D. Dake, Kimihiro Komori et al.|Journal of Endovascular Therapy|2020Cited by 12